A Two-Biomarker Signal for Alzheimer’s Disease
Dual plasma biomarkers may improve identification of established Alzheimer’s disease and signal faster decline
By
Henry Thomas
March 30, 2026
Clinical Scorecard: A Two-Biomarker Signal for Alzheimer’s Disease
At a Glance
Category Detail
Condition Alzheimer’s Disease Key Mechanisms Combination of plasma biomarkers p-tau217 and eMTBR-tau243 to identify tau pathology and cognitive impairment. Target Population Patients with cognitive symptoms including subjective cognitive decline, mild cognitive impairment, or dementia. Care Setting Secondary memory clinics and research settings.
Key Highlights
Combination of p-tau217 and eMTBR-tau243 improves identification of established Alzheimer’s disease. 81% accuracy and 84% positive predictive value for established disease with combined biomarkers. eMTBR-tau243 levels correlate with tau accumulation and cognitive decline. Two-step testing strategy enhances diagnostic precision. Study population included 572 patients with cognitive symptoms. Guideline-Based Recommendations
Diagnosis
Use plasma p-tau217 to detect amyloid pathology. Follow with eMTBR-tau243 to assess tau pathology. Management
Consider therapies targeting amyloid or tau based on biomarker levels. Monitoring & Follow-up
Monitor cognitive performance and tau PET signal over time. Risks
Potential for misclassification of asymptomatic amyloid pathology. Patient & Prescribing Data
Patients with cognitive symptoms and positive plasma p-tau217 results.
Higher eMTBR-tau243 levels indicate greater tau burden and faster cognitive decline.
Clinical Best Practices
Implement a two-step biomarker testing strategy in clinical assessments. Stratify patients based on biomarker results for tailored management. References
